



Attorney Docket No.: VPI/02-110 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Knegtel et al.
CONFIRMATION NO.: 6705
SERIAL NUMBER: 10/609,147 EXAMINER: Not Yet Assigned
FILING DATE: June 27, 2003 ART UNIT: 1614
FOR: CASPASE INHIBITORS AND USES THEREOF

February 26, 2004
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants hereby make of record the documents listed on the modified Form PTO-1449 (submitted in duplicate) in the above-identified application.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required (37 C.F.R. §1.97).


A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Knegt, et al.
U.S.S.N.: 10/609,147

Applicants also request that 1) a copy of the enclosed form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication; and 2) the enclosed be printed on any patent that may issue for this application.

The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment to Deposit Account No. 50-0725, Reference No. VPI/02-110 US.

Respectfully submitted,



Lisa A. Dixon and Reg. No. 40,995
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6396
Fax: (617) 444-6483



Our Docket No.: VPI/02-110 US

Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On February 26, 2004
Date

1. Information Disclosure Statement (in duplicate);
2. PTO-1449 Form (in duplicate); and
3. Cited References (B1-B3);
4. This Return Postcard Receipt.


Signature

Karen DiRocco
Typed or printed name of person signing Certificate



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/609,147
	Filing Date	June 27, 2003
	First Named Inventor	Ronald Knegtetl
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-110 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO	03/068242	Vertex Pharmaceuticals Incorporated	21 August 2003		
	B2	WO	01/42216	Vertex Pharmaceuticals Incorporated	14 June 2001		
	B3	DD	232 699	Akademie der Wissenschaften der DDR	5 February 1986		

OTHER NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.